China is cracking down on the loosely regulated clinical trials that have enabled its rapid rise as a global biomedical research hub. For years, researchers in China could launch investigator-initiated trials (IITs) largely on their own authority, without approval from China’s NMPA. This flexibility let physicians move quickly from lab findings to human testing, ultimately helping drugs obtain approval faster.
On the other hand, this flexibility resulted in a system where clinical trial outcomes routinely went unreported when they failed. Oversight quality varied significantly from hospital to hospital. Western drug developers conducting clinical studies in China have also raised concerns about intellectual property theft. The risks were underscored by recent cases, including the death of a young patient in a gene-editing trial.
In response, in October 2025, the State Council issued sweeping new rules, known as Order 818, that tighten how IITs are registered, conducted, and overseen. The regulations restrict which investigators and clinics can run IITs, require preliminary lab and animal research before human testing begins, and mandate that results be reported to the national health authority rather than provincial regulators.
U.S. companies have also used China’s trial system to get faster, cheaper results, so the American biotech industry is watching closely to see how strict the new rules end up being.